XTX Topco Ltd Makes New $500,000 Investment in Verve Therapeutics, Inc. (NASDAQ:VERV)

XTX Topco Ltd acquired a new stake in Verve Therapeutics, Inc. (NASDAQ:VERV) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 103,348 shares of the company’s stock, valued at approximately $500,000. XTX Topco Ltd owned 0.12% of Verve Therapeutics at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Nisa Investment Advisors LLC grew its stake in Verve Therapeutics by 908.4% in the 2nd quarter. Nisa Investment Advisors LLC now owns 7,714 shares of the company’s stock valued at $38,000 after acquiring an additional 6,949 shares during the period. Creative Planning acquired a new stake in shares of Verve Therapeutics in the third quarter valued at about $50,000. PFG Investments LLC acquired a new position in shares of Verve Therapeutics during the 3rd quarter worth about $53,000. Erste Asset Management GmbH acquired a new position in shares of Verve Therapeutics during the 3rd quarter worth about $56,000. Finally, Daiwa Securities Group Inc. lifted its stake in Verve Therapeutics by 89.8% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,094 shares of the company’s stock valued at $59,000 after buying an additional 5,723 shares in the last quarter. 97.11% of the stock is owned by institutional investors and hedge funds.

Verve Therapeutics Stock Performance

NASDAQ:VERV opened at $5.71 on Friday. The stock has a 50 day moving average price of $5.71 and a 200 day moving average price of $5.65. The stock has a market cap of $483.41 million, a PE ratio of -2.32 and a beta of 1.71. Verve Therapeutics, Inc. has a one year low of $4.30 and a one year high of $19.34.

Verve Therapeutics (NASDAQ:VERV) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.70) by $0.11. The business had revenue of $6.87 million for the quarter, compared to analyst estimates of $2.75 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The company’s quarterly revenue was up 120.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.72) EPS. As a group, analysts predict that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on VERV shares. Royal Bank of Canada reduced their target price on Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. Canaccord Genuity Group raised their price objective on Verve Therapeutics from $29.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. Finally, HC Wainwright dropped their target price on shares of Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday, November 6th.

Verve Therapeutics Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.